✦ LIBER ✦

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

✍ Scribed by Doody, Rachelle S.; Thomas, Ronald G.; Farlow, Martin; Iwatsubo, Takeshi; Vellas, Bruno; Joffe, Steven; Kieburtz, Karl; Raman, Rema; Sun, Xiaoying; Aisen, Paul S.; Siemers, Eric; Liu-Seifert, Hong; Mohs, Richard

Book ID: 121799376
Publisher: Massachusetts Medical Society
Year: 2014
Tongue: English
Weight: 514 KB
Volume: 370
Category: Article
ISSN: 0096-6762
DOI: 10.1056/NEJMoa1312889

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Solanezumab for the treatment of mild-to

Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease

✍ Imbimbo, Bruno P; Ottonello, Simone; Frisardi, Vincenza; Solfrizzi, Vincenzo; Gr 📂 Article 📅 2012 🏛 Expert Reviews 🌐 English ⚖ 887 KB

Two Phase 3 Trials of Bapineuzumab in Mi

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

✍ Salloway, Stephen; Sperling, Reisa; Fox, Nick C.; Blennow, Kaj; Klunk, William; 📂 Article 📅 2014 🏛 Massachusetts Medical Society 🌐 English ⚖ 620 KB

Efficacy and Safety of Intravenous Solan

Efficacy and Safety of Intravenous Solanezumab in Patients with Mild to Moderate Alzheimer's Disease: Results of Two Phase 3 Studies

✍ Hake, Ann M.; Siemers, Eric; Carlson, Christopher; Estergard, Wahiba; Sundell, K 📂 Article 📅 2013 🏛 American Psychiatric Publishing Inc 🌐 English ⚖ 50 KB

Effects of solanezumab versus placebo ad

Effects of solanezumab versus placebo administration on biomarkers in people with mild-to-moderate Alzheimer's disease: Results from two phase III clinical trials

✍ Dean, Robert; Siemers, Eric; Carlson, Christopher; Estergard, Wahiba; Sundell, K 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Efficacy of solanezumab in patients with

Efficacy of solanezumab in patients with mild or moderate Alzheimer's disease: Pooled analyses findings from two phase III studies

✍ Carlson, Christopher; Sundell, Karen; Estergard, Wahiba; Raskin, Joel; Liu-Seife 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 54 KB

Results of the GAP 160701 study: A phase

Results of the GAP 160701 study: A phase 3 clinical trial of intravenous immunoglobulin for mild-to-moderate Alzheimer's disease

✍ Relkin, Norman 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 54 KB